Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus

NCT00540462 — Phase 4, Unknown, 120 participants, Min-Sheng General Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT00540462, acronym T2DM
StatusUnknown
PhasePhase 4
Study typeInterventional; randomized, parallel, masking: triple, treatment
Enrollment120 (Estimated)
SponsorMin-Sheng General Hospital (Other)
ConditionsType II Diabetes Mellitus
Interventionsgastric bypass, sleeve gastrectomy (Procedure)
Datesstart 2007-08-01, primary completion 2008-08-01 (estimated), completion 2008-12-01 (estimated), first posted 2007-10-08, last updated 2008-11-14
Locations1 site in Taiwan

Related Papers Related Patents Related Grants Related Experts
All trials for Type II Diabetes Mellitus All trials of gastric bypass All trials of sleeve gastrectomy

-Summary

Although intensive medical treatment of diabetes has clearly been demonstrated to be worthwhile, it has not been a total success in diabetes treatment for a variety of reasons including lack of response to medication. Diabetes has been well demonstrated as a co-morbidity illness of obesity patients. In observation, with exclusion stomach and duodenum of bariatric surgery (gastric bypass), most morbidly obese patients (about 80%) with diabetes had a significant improved of sugar control. Base of this observation, we will try to find out the role surgical intervention (gastric bypass \& sleeve gastrectomy) in obese-related diabetes.

Expand all sections  ·  Collapse all

+Detailed description

In observation, with exclusion stomach and duodenum of bariatric surgery (gastric bypass), most morbidly obese patients (about 80%) with diabetes had a significant improved of sugar control. Base on this observation, we will try to find out the role surgical intervention (gastric bypass and sleeve gastrectomy) in obese-related diabetes. With restriction of stomach volume and with or without duodenal exclusion, this randomized trials will find out the role of duodenal exclusion and the role of Ghrenin in obese-related type II DM patients. The initial observation of previous morbidly obese patients with type II DM, the DM seems a chronic disease which could be treated or controlled by surgical intervention, that's what we try to know more.

+Arms and interventions

ArmTypeInterventionsDescription
1No interventionMedical Group
2Active comparatorProcedure: gastric bypassSurgical Group with gastric bypass
3Active comparatorProcedure: sleeve gastrectomySugical Group with Sleeve gastrectomy
  • gastric bypass (Procedure)
  • sleeve gastrectomy (Procedure)

+Outcome measures

Primary outcomes

  • Measure sugar levels, HbA1c levels, and medication needed. OGTT, MGTT. [1st, 2nd, 3rd, 4th, 5th, 6th, 9th, 12th months]

Secondary outcomes

  • Comparing the DM controls between Medical and Surgical treatment In surgery groups, compare the bypass surgery and sleeve gastrectomy [1 yr]

+Eligibility

Sex: All, ages: 30 Years to 60 Years

Inclusion Criteria:

* Patient with diagnosis of T2DM for at least 6 months
* Mild to moderate obesity status(BMI 27 - 35 )
* Age : 30 - 60 year-old
* HbA1C > 8 %

Exclusion Criteria:

* With co-morbidity illness of cardiovascular system
* DM related nephropathy (Cre >2.0 mg/dl)
* Pulmonary embolism or uncontrolled coagulopathy in 6 months
* HBV or HCV hepatitis or liver cirrhosis, inflammatory colon disease, Cushing syndrome
* s/p organ transplantation
* Previously Bariatric surgery, gastrointestinal surgery, or abdominal sepsis
* Alcoholic or drug abuser
* Psychological disease.
* HIV or TB patient

+Locations (1)

FacilityCityCountryStatus
MinSheng Genral HospitalTaoyuanTaiwanRecruiting

+Publications

  • Results publication: Lee WJ, Chong K, Ser KH, Lee YC, Chen SC, Chen JC, Tsai MH, Chuang LM. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011 Feb;146(2):143-8. doi: 10.1001/archsurg.2010.326. PMID 21339423

+Investigators